Literature DB >> 23648417

Beneficial effect of dehydroepiandrosterone on pulmonary hypertension in a rodent model of pulmonary hypertension in infants.

Eric Dumas de la Roque1, Jean-François Quignard, Thomas Ducret, Diana Dahan, Arnaud Courtois, Hugues Begueret, Roger Marthan, Jean-Pierre Savineau.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a disease that affects the adult or infant population. Dehydroepiandrosterone (DHEA), a steroid hormone, has been previously shown to prevent and to reverse PH in an adult rat model. We thus investigated its effect in a rat-pup model of chronic hypoxic PH.
METHODS: Animals were maintained for 3 wk in a hypobaric chamber to induce PH, with or without concomitant treatment with DHEA (30 mg/kg every alternate day).
RESULTS: DHEA significantly reduced mean pulmonary artery pressure (measured by right cardiac catheterization), pulmonary artery remodeling (evaluated by histology), and right-ventricular hypertrophy (measured by echography and by the Fulton index). At the level of the pulmonary artery smooth muscle cell (PASMC), DHEA increased activity and expression of the large-conductance Ca2+-activated potassium channel (BKCa) (assessed by means of the patch clamp technique). DHEA also inhibited both serotonin- and KCl-induced contraction and smooth muscle cell proliferation.
CONCLUSION: Collectively, these results indicate that DHEA prevents PH in infant rats and may therefore be clinically relevant for the management of PH in human infants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648417     DOI: 10.1038/pr.2013.73

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

Review 1.  Dehydroepiandrosterone (DHEA): hypes and hopes.

Authors:  Krzysztof Rutkowski; Paweł Sowa; Joanna Rutkowska-Talipska; Anna Kuryliszyn-Moskal; Ryszard Rutkowski
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

3.  Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).

Authors:  Michael B Fallon; Steven M Kawut; Nadine Al-Naamani; Michael J Krowka; Kimberly A Forde; Karen L Krok; Rui Feng; Gustavo A Heresi; Raed A Dweik; Sonja Bartolome; Todd M Bull; Kari E Roberts; Eric D Austin; Anna R Hemnes; Mamta J Patel; Jae K Oh; Grace Lin; Margaret F Doyle; Nina Denver; Ruth Andrew; Margaret R MacLean
Journal:  Hepatology       Date:  2020-09-29       Impact factor: 17.425

Review 4.  Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension.

Authors:  Tanvirul Hye; Pankaj Dwivedi; Wei Li; Tim Lahm; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-03-10       Impact factor: 6.011

5.  Activation of PPARγ by baicalin attenuates pulmonary hypertension in an infant rat model by suppressing HMGB1/RAGE signaling.

Authors:  Zhenjie Chen; Qiuxia Wang
Journal:  FEBS Open Bio       Date:  2017-03-08       Impact factor: 2.693

6.  Vasodilator effects of dehydroepiandrosterone (DHEA) on fetal pulmonary circulation: An experimental study in pregnant sheep.

Authors:  Dyuti Sharma; Hélène Coridon; Estelle Aubry; Ali Houeijeh; Véronique Houfflin-Debarge; Rémi Besson; Philippe Deruelle; Laurent Storme
Journal:  PLoS One       Date:  2018-06-27       Impact factor: 3.240

Review 7.  Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.

Authors:  Stevan P Tofovic; Edwin K Jackson
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.